Trials / Unknown
UnknownNCT00707681
Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
A Phase II Randomized, Controlled Study to Evaluate the Quality of Life, Survival and Therapeutic Benefits of MS-20 in Patient With Advanced Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Microbio Co Ltd · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients using European Organization for Research and Treatment of Cancer (EORTC) QLQ C-30 questionnaire.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MS-20 | 4 ml/vial |
| DRUG | Placebo | 4ml/vial |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2008-07-01
- Last updated
- 2010-02-26
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00707681. Inclusion in this directory is not an endorsement.